Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesThe history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor
Haemophilia, 11/17/06
Négrier.C, et al. - The development of alloantibodies that inhibit the function of factor VIII (FVIII) or factor IX (FIX) is the most serious complication associated with the treatment of haemophilia. Bleeding events in patients with high-titre inhibitors generally cannot be managed with factor replacement therapy and require alternative strategies for haemostatic support
| Previous Article | Next Article |
Today in Coagulation/Bleeding Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment
Best Practice & Research: Clinical Haematology , 06/12/09
The coagulopathy of acute promyelocytic leukaemia revisited
Best Practice & Research: Clinical Haematology , 06/18/09
JAK2V617F-Positive Latent Essential Thrombocythemia and Splanchnic Vein Thrombosis: The Role of Bone Marrow Biopsy for the Diagnosis of Myeloproliferative Disease
Acta Haematologica, 06/01/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Neoadjuvant chemotherapy for locally advanced breast cancer: a single center experience
Medical Oncology, 06/05/09
American Society of Clinical Oncology Clinical Practice Guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction
Journal of Clinical Oncology, 07/01/09
nab-paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial
Breast Cancer Research and Treatment, 06/09/09
Sponsor
Article Search
Sponsor